Table 1.
Evolution of catatonia under different treatments.
| Period | January 2021 | February 2021 | March 2021 | April 2021–June 2021 | July 2021 | August 2021–October 2021 | November 2021 | December 2021 | December 2021–February 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Brain stimulation treatment | 10 ECTs sessions 2 ECTs/week |
Maintenance ECTs 2 ECTs/month |
Covid-19 pressure
ECT withdrawal |
7 ECTs sessions | Covid-19 pressure Irregular maintenance ECT |
Covid-19 pressure Only 4 ECTs sessions with premature withdrawal. 10 tDCS session 2 sessions/day × 2 weeks |
Covid-19 pressure ECT unavailable 50 tDCS 5 tDCS/day X 10 days |
Covid-19 pressure ECT unavailable 150 tDCS with gradual decrease 5 tDCS/day × 5 days/week 5 tDCS/day × 3 days/week 5 tDCS/day × 2 days/week |
|
| Pharmacological treatment | Lorazepam trial and Zolpidem trial |
Olanzapine 20 mg/day | Olanzapine 20 mg/day | Olanzapine 20 mg/day | Olanzapine 20 mg/day | Olanzapine 20 mg/day | Olanzapine 20 mg/day | Olanzapine 20 mg/day | Olanzapine 20 mg/day |
| Outcome | No improvement | Remission | Remission | Relapse | Improvement | Relapse | Partial improvement | Improvement | Remission |
| BF | 40 | 0 | 0 | 40 | 3 | 40 | 36 | 13 | 3 |
BF, Bush-Francis Catatonia Rating Scale; ECT, Electroconvulsive therapy; tDCS, transcranial Direct Current Stimulation; Covid-19, coronavirus disease 2019 pandemic.